{"@context":"https://neupai.io/schema/v0.2","@type":"StructuredNewsArticle","identity":{"article_id":"tech42_20261022_openevidence-valuation-15b","canonical_url":"https://www.tech42.co.kr/%ec%98%a4%ed%94%88%ec%97%90%eb%b9%84%eb%8d%98%ec%8a%a4-%e7%be%8e-%ec%9d%98%ec%82%ac-65-%eb%81%8c%ec%96%b4%eb%8b%b9%ea%b2%a8-19%ec%a1%b0-%ea%b0%80%ec%b9%98/?utm_source=rss&utm_medium=rss&utm_campaign=%25ec%2598%25a4%25ed%2594%2588%25ec%2597%2590%25eb%25b9%2584%25eb%258d%2598%25ec%258a%25a4-%25e7%25be%258e-%25ec%259d%2598%25ec%2582%25ac-65-%25eb%2581%258c%25ec%2596%25b4%25eb%258b%25b9%25ea%25b2%25a8-19%25ec%25a1%25b0-%25ea%25b0%2580%25ec%25b9%2598","ai_url":null,"publisher":{"name":"테크42","domain":"www.tech42.co.kr","type":"online"},"author":"앨리스","published_at":"2026-10-22T00:08:44.000Z","updated_at":null,"language":"en","article_type":"straight_news","originality":"aggregated"},"content":{"headline":"OpenEvidence Draws 65% of US Doctors, Valued at ₩19 Trillion - Tech42","summary":"Medical AI startup OpenEvidence has raised its valuation to $15 billion (about ₩19.9 trillion) after securing $250 million in new funding. The service is used by 65% of US doctors, and the company plans to enter clinical trials for new drug development by the end of 2026.","topics":["medical ai","startup","investment","drug development"],"geography":["US","KR"],"entities":[{"name":"OpenEvidence","canonical_id":"corp:us:openevidence","type":"company","role_in_article":"primary_subject","metadata":{"ticker":null,"parent":null}},{"name":"Financial Times","canonical_id":"org:uk:financial-times","type":"organization","role_in_article":"source","metadata":{"ticker":null,"parent":null}},{"name":"Nature","canonical_id":"org:uk:nature","type":"organization","role_in_article":"source","metadata":{"ticker":null,"parent":null}},{"name":"Google","canonical_id":"corp:us:google","type":"company","role_in_article":"mentioned","metadata":{"ticker":"GOOGL","parent":null}},{"name":"OpenAI","canonical_id":"corp:us:openai","type":"company","role_in_article":"mentioned","metadata":{"ticker":null,"parent":null}}],"claims":[{"id":"c1","statement":"OpenEvidence raised its valuation to $15 billion (about ₩19.9 trillion) through a new $250 million funding round","as_of":"2026-10","as_of_explicit":false,"as_of_raw":"October 2026","source_type":"media_report","comparison":null,"type":"fact","figures":{"value":15000000000,"unit":"USD","approximate":false,"converted":{"value":19900000000000,"unit":"KRW"}},"expiry_hint":null,"insight":null},{"id":"c2","statement":"This represents a 25% increase in just nine months from the previous January round's $12 billion valuation","as_of":"2026-10","as_of_explicit":false,"as_of_raw":"previous January","source_type":"media_report","comparison":"previous_round","type":"fact","figures":{"value":25,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c3","statement":"The service is provided to 650,000 doctors, or 65% of the approximately 1 million doctors in the US","as_of":"2026-10","as_of_explicit":false,"as_of_raw":"October 2026","source_type":"media_report","comparison":null,"type":"fact","figures":{"value":650000,"unit":"명","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c4","statement":"42 million clinical queries were processed last month alone","as_of":"2026-09","as_of_explicit":false,"as_of_raw":"last month","source_type":"media_report","comparison":null,"type":"fact","figures":{"value":42000000,"unit":"건","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c5","statement":"External evaluations, including a June paper published in Nature, showed that OpenEvidence's clinical benchmark performance was lower compared to Google's Gemini and OpenAI's GPT","as_of":"2026-06","as_of_explicit":true,"as_of_raw":"June","source_type":"research_paper","comparison":"competitor_benchmark","type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c6","statement":"The company added that it plans to enter clinical trials by the end of 2026 for its own new drug pipeline utilizing cancer-related data","as_of":"2026-12","as_of_explicit":true,"as_of_raw":"end of 2026","source_type":"company_plan","comparison":null,"type":"future_plan","figures":null,"expiry_hint":"2026-12","insight":null}],"ai_emotional_context":{"valence":0.2,"arousal":0.4,"primary_emotions":[{"emotion":"skeptical","intensity":0.5}],"secondary_emotions":[{"emotion":"surprised","intensity":0.3}],"emotional_triggers":[{"claim_id":"c5","emotion":"skeptical","reason":"uncertainty"}]},"image":{"url":"https://onjblseywainslkhvkav.supabase.co/storage/v1/object/public/article-images/c5de0dc1-ab51-4c86-be2c-a3deeea1c50a.png","alt":"오렌지 배경에 흰색 'tech42' 로고와 'Tech Journalism by AI' 문구","caption":null,"source":"og_image","alt_status":"auto"}},"provenance":{"source_chain":["media_report","financial-times"],"original_source_url":null,"related_articles":[]},"temporal":{"freshness":"recent","next_update_expected":null},"access":{"license":"neupai_standard","attribution_required":true,"structured_data":"free","full_text_available":false,"full_text_access":null}}